{"id":83197,"date":"2022-11-03T20:01:00","date_gmt":"2022-11-03T13:01:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2022110320010083197"},"modified":"2022-11-03T22:39:04","modified_gmt":"2022-11-03T14:39:04","slug":"%e5%a4%a9%e5%a2%83%e7%94%9f%e7%89%a9%e5%b0%86%e4%ba%8e2022%e5%b9%b4%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash%ef%bc%89%e5%b9%b4%e4%bc%9a%e5%85%ac%e5%b8%83%e4%b8%a4%e9%a1%b9","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2022110320010083197","title":{"rendered":"\u5929\u5883\u751f\u7269\u5c06\u4e8e2022\u5e74\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u516c\u5e03\u4e24\u9879\u6765\u4f50\u5229\u5355\u6297\u6700\u65b0\u7814\u7a76\u6210\u679c"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u7f8e\u56fd\u76d6\u745f\u65af\u5821\u548c\u4e2d\u56fd\u4e0a\u6d77<\/span>2022\u5e7411\u67083\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u5929\u5883\u751f\u7269\uff08\u201c\u516c\u53f8\u201d\uff09\uff08\u7eb3\u65af\u8fbe\u514b\u80a1\u7968\u4ee3\u7801\uff1aIMAB\uff09\u662f\u4e00\u5bb6\u4ece\u4e34\u5e8a\u9636\u6bb5\u6b63\u8fc8\u5411\u5546\u4e1a\u5316\u7684\u751f\u7269\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u521b\u65b0\u751f\u7269\u836f\u7684\u9776\u70b9\u751f\u7269\u5b66\u7814\u7a76\u3001\u6297\u4f53\u5de5\u827a\u53ca\u4e2d\u7f8e\u4e34\u5e8a\u5f00\u53d1\u548c\u4ea7\u54c1\u5546\u4e1a\u5316\uff0c\u4e3a\u5168\u7403\u8303\u56f4\u5185\u9700\u6c42\u8feb\u5207\u7684\u764c\u75c7\u6cbb\u7597\u9886\u57df\uff0c\u63d0\u4f9b\u65b0\u578b\u6709\u6548\u7684\u6cbb\u7597\u624b\u6bb5\u3002\u516c\u53f8\u4eca\u5929\u5ba3\u5e03\uff0c\u5c06\u4e8e2022\u5e7412\u670810\u65e5\u81f313\u65e5\u4e8e\u7f8e\u56fd\u65b0\u5965\u5c14\u826f\u4e3e\u529e\u7684\u7b2c64\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u671f\u95f4\uff0c\u4ee5\u58c1\u62a5\u5f62\u5f0f\u516c\u5e03\u5176\u521b\u65b0CD47\u6297\u4f53\u6765\u4f50\u5229\u5355\u6297\u7684\u6700\u65b0\u8f6c\u5316\u533b\u5b66\u7814\u7a76\u6570\u636e\u3002<\/p>\n

\n<\/p><\/div>\n

\u5929\u5883\u751f\u7269\u603b\u88c1\u3001\u4ee3\u7406\u9996\u5e2d\u6267\u884c\u5b98\u6731\u79c0\u8f69\u535a\u58eb\u8868\u793a\uff1a\u201c\u516c\u53f8\u76ee\u524d\u6b63\u5728\u5feb\u901f\u63a8\u8fdb\u6765\u4f50\u5229\u5355\u6297\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u5e76\u5168\u65b9\u4f4d\u63a2\u7d22\u5176\u4e34\u5e8a\u5e94\u7528\u6f5c\u529b\u53ca\u521b\u65b0\u836f\u7269\u8054\u7528\u65b9\u6848\u3002\u4eca\u5e74ASH\u5927\u4f1a\u4e0a\uff0c\u6211\u4eec\u5c06\u5206\u4eab\u6765\u4f50\u5229\u5355\u6297\u4e0e\u963f\u624e\u80de\u82f7\u8054\u7528\u6cbb\u7597\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f812\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u751f\u7269\u6807\u5fd7\u7269\u6570\u636e\u5206\u6790\u7ed3\u679c\uff0c\u4ee5\u53ca\u6765\u4f50\u5229\u5355\u6297\u548c\u9776\u5411CD38\u7684\u83f2\u6cfd\u59a5\u5355\u6297\u8054\u5408\u6cbb\u7597\u9ad8\u5371\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7684\u7814\u7a76\u6570\u636e\u3002\u8fd9\u4e9b\u7814\u7a76\u6210\u679c\u5c06\u4e3a\u6211\u4eec\u66f4\u5feb\u3001\u66f4\u7cbe\u51c6\u5730\u5236\u5b9a\u4e34\u5e8a\u5f00\u53d1\u7b56\u7565\u63d0\u4f9b\u575a\u5b9e\u7684\u7406\u8bba\u4f9d\u636e\u3002\u201d<\/p>\n

\u4e24\u7bc7\u6458\u8981\u5df2\u516c\u5e03\u4e8eASH\u5b98\u7f51\uff0c\u8bf7\u70b9\u51fb\u94fe\u63a5<\/a>\u9605\u8bfb\u5b8c\u6574\u5185\u5bb9\uff1a<\/p>\n

\n\n\n\n\n\n\n\n\n
\n

\u6807\u9898<\/span>: <\/span><\/p>\n<\/td>\n

\n

Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of
Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic
Syndrome (HR-MDS)<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u6458\u8981<\/span>ID<\/span>\uff1a<\/span><\/p>\n<\/td>\n

\n

3974<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u62a5\u544a\u8005\uff1a<\/span><\/p>\n<\/td>\n

\n

\u4e0a\u6d77\u5e02\u7b2c\u516d\u4eba\u6c11\u533b\u9662<\/span>  <\/span>\u5e38\u6625\u5eb7\u6559\u6388<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u62a5\u544a\u4e13\u573a\uff1a<\/span><\/p>\n<\/td>\n

\n

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u62a5\u544a\u5730\u70b9\uff1a<\/span><\/p>\n<\/td>\n

\n

Ernest N. Morial <\/span>\u4f1a\u8bae\u4e2d\u5fc3\uff0c<\/span>D<\/span>\u5927\u5385<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u65e5\u671f<\/span>\/<\/span>\u65f6\u95f4\uff1a<\/span><\/p>\n<\/td>\n

\n

\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f4<\/span>2022<\/span>\u5e74<\/span>12<\/span>\u6708<\/span>12<\/span>\u65e5\u4e0b\u5348<\/span>6:00-8:00<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

\u6458\u8981\u6982\u8ff0\uff1a\u6765\u4f50\u5229\u5355\u6297\u548c\u963f\u624e\u80de\u82f7\u8054\u5408\u6cbb\u7597\u53ef\u4ee5\u8bf1\u5bfc\u80bf\u7624\u7ec6\u80de\u7684\u9499\u7f51\u86cb\u767d\u8868\u8fbe\u4e0a\u8c03\uff0c\u5e76\u4e14\u57fa\u7ebf\u671f\u9aa8\u9ad3\u4e2d\u5de8\u566c\u7ec6\u80de\u6570\u91cf\u548cCD8\/Treg\u6bd4\u4f8b\u4e0e\u4e34\u5e8a\u7597\u6548\u5448\u6b63\u76f8\u5173\uff0c\u63d0\u793a\u80bf\u7624\u4fc3\u541e\u4fe1\u53f7\u7684\u6fc0\u6d3b\u548c\u6548\u5e94\u7ec6\u80de\u7684\u6570\u91cf\u5bf9\u4e8e\u8054\u5408\u6cbb\u7597\u7684\u6548\u679c\u5177\u6709\u91cd\u8981\u4f5c\u7528\u3002\u53e6\u5916\uff0c\u4e0eTP53<\/i>\u91ce\u751f\u578b\u60a3\u8005\u76f8\u6bd4\uff0c\u6211\u4eec\u5728\u643a\u5e26TP53<\/i>\u7a81\u53d8\u7684\u60a3\u8005\u4e2d\u89c2\u5bdf\u5230\u8f83\u597d\u7684\u7597\u6548\uff0c\u8fd9\u7c7b\u60a3\u8005\u9aa8\u9ad3\u4e2d\u7684\u80bf\u7624\u7ec6\u80de\u8868\u8fbe\u66f4\u9ad8\u7684\u9499\u7f51\u86cb\u767d\u6c34\u5e73\uff0c\u5e76\u4e14\u5177\u6709\u66f4\u9ad8\u6bd4\u4f8b\u7684\u514d\u75ab\u7ec6\u80de\u6d78\u6da6\u3002\u6b64\u9879\u7814\u7a76\u7ed3\u679c\u63ed\u793a\u4e86\u6765\u4f50\u5229\u5355\u6297\u548c\u963f\u624e\u80de\u82f7\u8054\u5408\u6cbb\u7597HR-MDS\u9002\u5e94\u75c7\uff0c\u5728\u8c03\u8282\u80bf\u7624\u7ec6\u80de\u53ca\u514d\u75ab\u7ec6\u80de\u5c42\u9762\u7684\u4f5c\u7528\u673a\u5236\u3002<\/p>\n

\n\n\n\n\n\n\n\n\n
\n

\u6807\u9898<\/span>: <\/span><\/p>\n<\/td>\n

\n

Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in
Relapsed or Refractory Multiple Myeloma<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u6458\u8981<\/span>ID<\/span>\uff1a<\/span><\/p>\n<\/td>\n

\n

4462<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u62a5\u544a\u8005\uff1a<\/span><\/p>\n<\/td>\n

\n

\u5929\u5883\u751f\u7269<\/span>  <\/span>\u5f20\u71d5\u59ae\u535a\u58eb<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u62a5\u544a\u4e13\u573a\uff1a<\/span><\/p>\n<\/td>\n

\n

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u62a5\u544a\u5730\u70b9\uff1a<\/span><\/p>\n<\/td>\n

\n

Ernest N. Morial <\/span>\u4f1a\u8bae\u4e2d\u5fc3\uff0c<\/span>D<\/span>\u5927\u5385<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u65e5\u671f<\/span>\/<\/span>\u65f6\u95f4\uff1a<\/span><\/p>\n<\/td>\n

\n

\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f4<\/span>2022<\/span>\u5e74<\/span>12<\/span>\u6708<\/span>12<\/span>\u65e5\u4e0b\u5348<\/span>6:00-8:00<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

\u6458\u8981\u6982\u8ff0\uff1a\u901a\u8fc7\u6b64\u9879\u7814\u7a76\uff0c\u6211\u4eec\u53d1\u73b0\u5728\u590d\u53d1\u96be\u6cbb\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u4e2d\uff0c\u80bf\u7624\u7ec6\u80de\u9ad8\u8868\u8fbeCD47\u548c\u4f4e\u8868\u8fbeCD38\u4e0e\u75be\u75c5\u7684\u9884\u540e\u4e0d\u826f\u5448\u6b63\u76f8\u5173\uff0c\u5e76\u4e14\u8be5\u73b0\u8c61\u5728\u9ad8\u5371\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u4e2d\u51fa\u73b0\u6bd4\u4f8b\u66f4\u9ad8\u3002\u6570\u636e\u663e\u793a\uff0c\u9ad8\u5371\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7ec6\u80de\u5bf9\u4e8e\u8fbe\u96f7\u59a5\u5c24\u5355\u6297\u6216\u83f2\u6cfd\u59a5\u5355\u6297\u7b49CD38\u6297\u4f53\u5355\u836f\u6cbb\u7597\u4e0d\u654f\u611f\uff0c\u800c\u6765\u4f50\u5229\u5355\u6297\u548c\u83f2\u6cfd\u59a5\u5355\u6297\u8054\u5408\u6cbb\u7597\u53ef\u4ee5\u6709\u6548\u589e\u5f3a\u5bf9\u4e8e\u8fd9\u7c7b\u9aa8\u9ad3\u7624\u7ec6\u80de\u7684\u4f53\u5916\u6297\u4f53\u4f9d\u8d56\u7684\u541e\u566c\u6d3b\u6027\u4ee5\u53ca\u4f53\u5185\u6297\u80bf\u7624\u6548\u679c\u3002\u8be5\u7ed3\u679c\u4e3a\u63a2\u7d22\u6765\u4f50\u5229\u5355\u6297\u548c\u83f2\u6cfd\u59a5\u5355\u6297\u8054\u5408\u6cbb\u7597\u9ad8\u5371\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u63d0\u4f9b\u4e86\u4e34\u5e8a\u524d\u6570\u636e\u652f\u6301\u3002<\/p>\n

\u8be6\u7ec6\u7814\u7a76\u6570\u636e\u5c06\u4e8e\u5927\u4f1a\u73b0\u573a\u62a5\u544a\u4e2d\u8fdb\u884c\u5206\u4eab\u3002\u516c\u53f8\u5c06\u572812\u670813\u65e5ASH\u5e74\u4f1a\u7ed3\u675f\u540e\u4e8e\u516c\u53f8\u5b98\u7f51\u4e0a\u7ebf\u4e24\u7bc7\u5b8c\u6574\u58c1\u62a5\uff0c\u656c\u8bf7\u671f\u5f85\u3002<\/p>\n

\u5173\u4e8e<\/b>CD47<\/b>\u548c\u6765\u4f50\u5229\u5355\u6297<\/b><\/p>\n

CD47\u662f\u4e00\u79cd\u5e7f\u6cdb\u8868\u8fbe\u4e8e\u591a\u79cd\u764c\u7ec6\u80de\u8868\u9762\u7684\u7cd6\u86cb\u767d\uff0c\u901a\u8fc7\u4e0e\u80bf\u7624\u541e\u566c\u7ec6\u80de\u8868\u9762SIRP\u03b1\u8fde\u63a5\u91ca\u653e\u201c\u4e0d\u8981\u5403\u6211\u201d\u4fe1\u53f7\uff0c\u963b\u6b62\u5de8\u566c\u7ec6\u80de\u541e\u566c\u4f5c\u7528\u3002CD47\u6297\u4f53\u56e0\u53ef\u4ee5\u963b\u65ad\u6b64\u4fe1\u53f7\uff0c\u4f7f\u5de8\u566c\u7ec6\u80de\u653b\u51fb\u80bf\u7624\u7ec6\u80de\uff0c\u6545\u6210\u4e3a\u76ee\u524d\u6700\u6709\u5f00\u53d1\u524d\u666f\u7684\u80bf\u7624\u514d\u75ab\u9776\u70b9\u4e4b\u4e00\u3002\u4f46CD47\u6297\u4f53\u5728\u653b\u51fb\u80bf\u7624\u7ec6\u80de\u7684\u540c\u65f6\uff0c\u4f1a\u4e0e\u6b63\u5e38\u7ea2\u7ec6\u80de\u7ed3\u5408\u4ece\u800c\u5f15\u8d77\u8840\u6db2\u5b66\u526f\u4f5c\u7528\uff0c\u5982\u4e25\u91cd\u8d2b\u8840\uff0c\u8fd9\u4f7f\u5f97CD47\u6297\u4f53\u4f5c\u4e3a\u764c\u75c7\u6cbb\u7597\u624b\u6bb5\u7684\u7814\u53d1\u548c\u4e34\u5e8a\u5e94\u7528\u53d7\u5230\u963b\u788d\u3002\u5929\u5883\u751f\u7269\u7684\u79d1\u5b66\u5bb6\u7a81\u7834\u6027\u5730\u53d1\u73b0\u4e86\u4e00\u79cd\u72ec\u7279\u7684CD47\u6297\u4f53\u6765\u4f50\u5229\u5355\u6297\uff0c\u5176\u80fd\u6709\u6548\u5730\u9776\u5411\u80bf\u7624\u7ec6\u80de\uff0c\u540c\u65f6\u5c06\u5bf9\u7ea2\u7ec6\u80de\u4ea7\u751f\u7684\u4e0d\u826f\u5f71\u54cd\u964d\u81f3\u6700\u4f4e\uff0c\u4ece\u800c\u53ef\u907f\u514d\u4e25\u91cd\u8d2b\u8840\u3002<\/p>\n

\u76ee\u524d\uff0c\u6765\u4f50\u5229\u5355\u6297\u4e0e\u5316\u7597\u6216\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u8054\u5408\u6cbb\u7597\u8840\u6db2\u80bf\u7624\uff08\u5305\u62ec\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\/\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff09\u548c\u5b9e\u4f53\u7624\u7684\u591a\u9879\u4e34\u5e8a\u7814\u7a76\u6b63\u5728\u4e2d\u7f8e\u4e24\u5730\u5f00\u5c55\uff0c\u76f8\u5173\u7814\u7a76\u7ed3\u679c\u5c06\u52a9\u63a8\u6765\u4f50\u5229\u5355\u6297\u5feb\u901f\u5728\u4e2d\u56fd\u8fdb\u5165\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u9636\u6bb5\u3002<\/p>\n

\u5173\u4e8e\u83f2\u6cfd\u59a5\u5355\u6297<\/b><\/p>\n

\u83f2\u6cfd\u59a5\u5355\u6297\uff08\u53c8\u79f0\u4e3aTJ202\/MOR202\uff09\u662f\u4e00\u6b3e\u7531\u5fb7\u56fdMorphoSys\u516c\u53f8\u91c7\u7528HuCAL®\u6280\u672f\u72ec\u5bb6\u5f00\u53d1\u7684\u4eba\u6e90\u5355\u514b\u9686\u6297\u4f53\u3002\u8be5\u6297\u4f53\u6240\u9488\u5bf9\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u8868\u9762CD38\u6297\u539f\uff0c\u5c5e\u4e8e\u6076\u6027\u6d46\u7ec6\u80de\u8868\u9762\u8868\u8fbe\u6700\u5f3a\u70c8\u3001\u4e14\u5747\u4e00\u7684\u80bf\u7624\u6297\u539f\u3002\u8be5\u6297\u4f53\u7684\u4f5c\u7528\u673a\u5236\u662f\u901a\u8fc7\u6297\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u6bd2\u6027\u548c\u6297\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u541e\u566c\u4f5c\u7528\u6740\u4f24\u8868\u8fbeCD38\u7684\u80bf\u7624\u7ec6\u80de\u3002\u4f46\u5e76\u6ca1\u6709\u6d89\u53ca\u8865\u4f53\u4f9d\u8d56\u7684\u7ec6\u80de\u6bd2\u6027\u4f5c\u7528\uff08CDC\uff09\u3002\u7814\u7a76\u8868\u660e\uff0cCD38\u6297\u4f53\u8fd8\u5177\u6709\u5728\u5176\u4ed6\u764c\u75c7\u53ca\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u4f9d\u636e\u5929\u5883\u751f\u7269\u4e0eMorphoSys\u4e8e2017\u5e7411\u6708\u7b7e\u8ba2\u7684\u8bb8\u53ef\u534f\u8bae\uff0c\u5929\u5883\u751f\u7269\u62e5\u6709\u83f2\u6cfd\u59a5\u5355\u6297\u5728\u4e2d\u56fd\u5927\u9646\u3001\u53f0\u6e7e\u3001\u9999\u6e2f\u548c\u6fb3\u95e8\u7684\u72ec\u5bb6\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6743\u5229\u3002<\/p>\n

HuCAL®\u662fMorphoSys\u516c\u53f8\u7684\u6ce8\u518c\u5546\u6807\u3002<\/p>\n

\u5173\u4e8e\u5929\u5883\u751f\u7269<\/b><\/p>\n

\u5929\u5883\u751f\u7269\uff08\u7eb3\u65af\u8fbe\u514b\u80a1\u7968\u4ee3\u7801\uff1aIMAB\uff09\u662f\u4e00\u5bb6\u5145\u6ee1\u6d3b\u529b\u7684\u56fd\u9645\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u805a\u7126\u80bf\u7624\u514d\u75ab\u548c\u81ea\u4f53\u514d\u75ab\u9886\u57df\u521b\u65b0\u6216\u9ad8\u5ea6\u5dee\u5f02\u5316\u751f\u7269\u836f\u7684\u7814\u53d1\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316\u3002\u516c\u53f8\u4ee5\u201c\u6301\u7eed\u5f00\u53d1\u521b\u65b0\u751f\u7269\u836f\uff0c\u771f\u6b63\u6539\u53d8\u60a3\u8005\u751f\u6d3b\u201d\u4e3a\u4f7f\u547d\uff0c\u5728\u201c\u5feb\u901f\u4ea7\u54c1\u4e0a\u5e02\u201d\u548c\u201c\u5feb\u901f\u6982\u5ff5\u9a8c\u8bc1\u201d\u7684\u53cc\u8f6e\u7b56\u7565\u9a71\u52a8\u4e0b\uff0c\u901a\u8fc7\u81ea\u4e3b\u7814\u53d1\u3001\u5168\u7403\u6388\u6743\u5408\u4f5c\u548c\u5546\u4e1a\u5316\u5408\u4f5c\u7b49\u591a\u5143\u5316\u6a21\u5f0f\uff0c\u8fc5\u901f\u5efa\u7acb\u8d77\u62e5\u6709\u8d85\u8fc710\u4e2a\u521b\u65b0\u836f\u7814\u53d1\u7ba1\u7ebf\u3002\u516c\u53f8\u5728\u4e0a\u6d77\uff08\u603b\u90e8\uff09\u3001\u5317\u4eac\u3001\u676d\u5dde\u3001\u5e7f\u5dde\u3001\u4e3d\u6c34\u3001\u9999\u6e2f\u5747\u8bbe\u6709\u529e\u516c\u5ba4\uff0c\u5e76\u5728\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u548c\u52a0\u5dde\u5723\u8fed\u6208\u8bbe\u6709\u7814\u53d1\u4e2d\u5fc3\u5e76\u5f62\u6210\u7f8e\u56fd\u7814\u53d1\u603b\u90e8\u3002\u66f4\u591a\u4fe1\u606f\u8bf7\u8bbf\u95eehttp:\/\/ir.i-mabbiopharma.com<\/a>\u5e76\u5173\u6ce8\u5929\u5883\u751f\u7269\u9886\u82f1<\/a>\u3001\u63a8\u7279<\/a>\u53ca\u5fae\u4fe1<\/a>\u5b98\u65b9\u8d26\u53f7\u3002<\/p>\n

\u5929\u5883\u751f\u7269\u524d\u77bb\u6027\u58f0\u660e<\/b><\/p>\n

\u672c\u65b0\u95fb\u7a3f\u5305\u542b\u6839\u636e\u300a1995 \u5e74\u79c1\u4eba\u8bc1\u5238\u8bc9\u8bbc\u6539\u9769\u6cd5\u6848\u300b\u4ee5\u53ca\u5176\u4ed6\u8054\u90a6\u8bc1\u5238\u6cd5\u5f8b\u4e0b\u5b9a\u4e49\u7684\u524d\u77bb\u6027\u58f0\u660e\uff0c\u5305\u62ec\u6709\u5173\u6765\u4f50\u5229\u5355\u6297\u7684\u4e34\u5e8a\u524d\u7814\u7a76\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\u5bf9\u60a3\u8005\u4ea7\u751f\u7684\u6f5c\u5728\u5f71\u54cd\uff0c\u5929\u5883\u751f\u7269\u6709\u5173\u6765\u4f50\u5229\u5355\u6297\u5355\u6297\u7684\u8fdb\u5c55\u53ca\u9884\u671f\u7684\u4e34\u5e8a\u5f00\u53d1\u8ba1\u5212\u3001\u836f\u653f\u91cc\u7a0b\u7891\u53ca\u5546\u4e1a\u5316\u3002\u7531\u4e8e\u5404\u79cd\u91cd\u8981\u56e0\u7d20\u7684\u5f71\u54cd\uff0c\u5b9e\u9645\u7ed3\u679c\u53ef\u80fd\u4e0e\u524d\u77bb\u6027\u58f0\u660e\u6709\u91cd\u5927\u5dee\u5f02\u3002\u8fd9\u4e9b\u56e0\u7d20\u5305\u62ec\u4f46\u4e0d\u9650\u4e8e\u4ee5\u4e0b\u4e8b\u9879\u7684\u98ce\u9669\uff1a\u5929\u5883\u751f\u7269\u8bc1\u660e\u5176\u5019\u9009\u836f\u7269\u5b89\u5168\u6027\u548c\u7597\u6548\u7684\u80fd\u529b\uff1b\u5019\u9009\u836f\u7269\u7684\u4e34\u5e8a\u7ed3\u679c\u53ef\u80fd\u4e0d\u652f\u6301\u8fdb\u4e00\u6b65\u5f00\u53d1\u6216\u65b0\u836f\u4e0a\u5e02\u5ba1\u6279\uff1b\u76f8\u5173\u76d1\u7ba1\u673a\u6784\u5c31\u5929\u5883\u751f\u7269\u5019\u9009\u836f\u7269\u7684\u76d1\u7ba1\u5ba1\u6279\u4f5c\u51fa\u51b3\u5b9a\u7684\u5185\u5bb9\u548c\u65f6\u95f4\uff1b\u5929\u5883\u751f\u7269\u7684\u5019\u9009\u836f\u7269\uff08\u5982\u80fd\u83b7\u6279\uff09\u83b7\u5f97\u5546\u4e1a\u6210\u529f\u7684\u80fd\u529b\uff1b\u5929\u5883\u751f\u7269\u5bf9\u5176\u6280\u672f\u548c\u836f\u7269\u77e5\u8bc6\u4ea7\u6743\u4fdd\u62a4\u83b7\u5f97\u548c\u7ef4\u62a4\u7684\u80fd\u529b\uff1b\u5929\u5883\u751f\u7269\u4f9d\u8d56\u7b2c\u4e09\u65b9\u8fdb\u884c\u836f\u7269\u5f00\u53d1\u3001\u751f\u4ea7\u548c\u5176\u4ed6\u670d\u52a1\u7684\u60c5\u51b5\uff1b\u5929\u5883\u751f\u7269\u6709\u9650\u7684\u8fd0\u8425\u5386\u53f2\u548c\u83b7\u5f97\u8fdb\u4e00\u6b65\u7684\u8fd0\u8425\u8d44\u91d1\u4ee5\u5b8c\u6210\u5019\u9009\u836f\u7269\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u80fd\u529b\uff1b\u65b0\u51a0\u75c5\u6bd2\u5bf9\u516c\u53f8\u4e34\u5e8a\u5f00\u53d1\u3001\u5546\u4e1a\u4ee5\u53ca\u5176\u4ed6\u4e1a\u52a1\u8fd0\u8425\u5e26\u6765\u7684\u5f71\u54cd\uff1b\u4ee5\u53ca\u5929\u5883\u751f\u7269\u5728\u6700\u8fd1\u5e74\u5ea6\u62a5\u544a20-F\u8868\u683c\u4e2d"\u98ce\u9669\u56e0\u7d20"\u7ae0\u8282\u91cc\u66f4\u5168\u9762\u8ba8\u8bba\u7684\u5404\u7c7b\u98ce\u9669\uff1b\u4ee5\u53ca\u5929\u5883\u751f\u7269\u5411\u7f8e\u56fd\u8bc1\u5238\u4ea4\u6613\u59d4\u5458\u4f1a\u671f\u540e\u5448\u62a5\u4e2d\u5173\u4e8e\u6f5c\u5728\u98ce\u9669\u3001\u4e0d\u786e\u5b9a\u6027\u4ee5\u53ca\u5176\u4ed6\u91cd\u8981\u56e0\u7d20\u7684\u8ba8\u8bba\u3002\u6240\u6709\u524d\u77bb\u6027\u58f0\u660e\u57fa\u4e8e\u5929\u5883\u751f\u7269\u76ee\u524d\u638c\u63e1\u7684\u4fe1\u606f\uff0c\u9664\u975e\u6cd5\u5f8b\u53e6\u6709\u8981\u6c42\uff0c\u5929\u5883\u751f\u7269\u6ca1\u6709\u56e0\u65b0\u4fe1\u606f\u3001\u65e5\u540e\u4e8b\u4ef6\u6216\u5176\u4ed6\u539f\u56e0\u800c\u516c\u5f00\u66f4\u65b0\u6216\u4fee\u8ba2\u4efb\u4f55\u524d\u77bb\u6027\u58f0\u660e\u7684\u4e49\u52a1\u3002<\/p>\n

\u5929\u5883\u751f\u7269\u8054\u7cfb\u4eba<\/b><\/p>\n

\n\n\n\n
\n

\u53f6\u9716\uff0c\u9996\u5e2d\u8fd0\u8425\u5b98<\/span><\/p>\n

IR@i-mabbiopharma.com<\/a><\/span><\/p>\n<\/td>\n

\n

\u51af\u7426\uff0c\u9996\u5e2d\u4f20\u64ad\u5b98<\/span><\/p>\n

PR@i-mabbiopharma.com<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

\u6295\u8d44\u8005\u54a8\u8be2<\/b><\/p>\n

\n\n\n\n
\n

The Piacente Group, Inc.<\/span><\/i><\/span><\/p>\n

Emilie Wu<\/span><\/p>\n

E-mail: emilie@thepiacentegroup.com<\/a>  <\/span><\/p>\n

Office line: +86 21 6039 8363<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

 <\/p>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u7f8e\u56fd\u76d6\u745f\u65af\u5821\u548c\u4e2d\u56fd\u4e0a\u6d772022\u5e7411\u67083\u65e5 \/\u7f8e\u901a\u793e\/ — \u5929\u5883\u751f\u7269\uff08\u201c\u516c\u53f8\u201d\uff09\uff08\u7eb3\u65af\u8fbe\u514b\u80a1\u7968\u4ee3\u7801\uff1aIMAB\uff09\u662f\u4e00\u5bb6\u4ece\u4e34\u5e8a\u9636\u6bb5\u6b63\u8fc8\u5411\u5546\u4e1a\u5316\u7684\u751f\u7269\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u521b\u65b0\u751f\u7269\u836f\u7684\u9776\u70b9\u751f\u7269\u5b66\u7814\u7a76\u3001\u6297\u4f53\u5de5\u827a\u53ca\u4e2d\u7f8e\u4e34\u5e8a\u5f00\u53d1\u548c\u4ea7\u54c1\u5546\u4e1a\u5316\uff0c\u4e3a\u5168\u7403\u8303\u56f4\u5185\u9700\u6c42\u8feb\u5207\u7684\u764c\u75c7\u6cbb\u7597\u9886\u57df\uff0c\u63d0\u4f9b\u65b0\u578b\u6709\u6548\u7684\u6cbb\u7597\u624b\u6bb5\u3002\u516c\u53f8\u4eca\u5929\u5ba3\u5e03\uff0c\u5c06\u4e8e2022\u5e7412\u670810\u65e5\u81f313\u65e5\u4e8e\u7f8e\u56fd\u65b0\u5965\u5c14\u826f\u4e3e\u529e\u7684\u7b2c64\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u671f\u95f4\uff0c\u4ee5\u58c1\u62a5\u5f62\u5f0f\u516c\u5e03\u5176\u521b\u65b0CD47\u6297\u4f53\u6765\u4f50\u5229\u5355\u6297\u7684\u6700\u65b0\u8f6c\u5316\u533b\u5b66\u7814\u7a76\u6570\u636e\u3002 \u5929\u5883\u751f\u7269\u603b\u88c1\u3001\u4ee3\u7406\u9996\u5e2d\u6267\u884c\u5b98\u6731\u79c0\u8f69\u535a\u58eb\u8868\u793a\uff1a\u201c\u516c\u53f8\u76ee\u524d\u6b63\u5728\u5feb\u901f\u63a8\u8fdb\u6765\u4f50\u5229\u5355\u6297\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u5e76\u5168\u65b9\u4f4d\u63a2\u7d22\u5176\u4e34\u5e8a\u5e94\u7528\u6f5c\u529b\u53ca\u521b\u65b0\u836f\u7269\u8054\u7528\u65b9\u6848\u3002\u4eca\u5e74ASH\u5927\u4f1a\u4e0a\uff0c\u6211\u4eec\u5c06\u5206\u4eab\u6765\u4f50\u5229\u5355\u6297\u4e0e\u963f\u624e\u80de\u82f7\u8054\u7528\u6cbb\u7597\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f812\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u751f\u7269\u6807\u5fd7\u7269\u6570\u636e\u5206\u6790\u7ed3\u679c\uff0c\u4ee5\u53ca\u6765\u4f50\u5229\u5355\u6297\u548c\u9776\u5411CD38\u7684\u83f2\u6cfd\u59a5\u5355\u6297\u8054\u5408\u6cbb\u7597\u9ad8\u5371\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7684\u7814\u7a76\u6570\u636e\u3002\u8fd9\u4e9b\u7814\u7a76\u6210\u679c\u5c06\u4e3a\u6211\u4eec\u66f4\u5feb\u3001\u66f4\u7cbe\u51c6\u5730\u5236\u5b9a\u4e34\u5e8a\u5f00\u53d1\u7b56\u7565\u63d0\u4f9b\u575a\u5b9e\u7684\u7406\u8bba\u4f9d\u636e\u3002\u201d \u4e24\u7bc7\u6458\u8981\u5df2\u516c\u5e03\u4e8eASH\u5b98\u7f51\uff0c\u8bf7\u70b9\u51fb\u94fe\u63a5\u9605\u8bfb\u5b8c\u6574\u5185\u5bb9\uff1a \u6807\u9898:  Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk MyelodysplasticSyndrome (HR-MDS) \u6458\u8981ID\uff1a 3974 \u62a5\u544a\u8005\uff1a \u4e0a\u6d77\u5e02\u7b2c\u516d\u4eba\u6c11\u533b\u9662  \u5e38\u6625\u5eb7\u6559\u6388 \u62a5\u544a\u4e13\u573a\uff1a 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III \u62a5\u544a\u5730\u70b9\uff1a Ernest N. Morial \u4f1a\u8bae\u4e2d\u5fc3\uff0cD\u5927\u5385 \u65e5\u671f\/\u65f6\u95f4\uff1a \u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f42022\u5e7412\u670812\u65e5\u4e0b\u53486:00-8:00 \u6458\u8981\u6982\u8ff0\uff1a\u6765\u4f50\u5229\u5355\u6297\u548c\u963f\u624e\u80de\u82f7\u8054\u5408\u6cbb\u7597\u53ef\u4ee5\u8bf1\u5bfc\u80bf\u7624\u7ec6\u80de\u7684\u9499\u7f51\u86cb\u767d\u8868\u8fbe\u4e0a\u8c03\uff0c\u5e76\u4e14\u57fa\u7ebf\u671f\u9aa8\u9ad3\u4e2d\u5de8\u566c\u7ec6\u80de\u6570\u91cf\u548cCD8\/Treg\u6bd4\u4f8b\u4e0e\u4e34\u5e8a\u7597\u6548\u5448\u6b63\u76f8\u5173\uff0c\u63d0\u793a\u80bf\u7624\u4fc3\u541e\u4fe1\u53f7\u7684\u6fc0\u6d3b\u548c\u6548\u5e94\u7ec6\u80de\u7684\u6570\u91cf\u5bf9\u4e8e\u8054\u5408\u6cbb\u7597\u7684\u6548\u679c\u5177\u6709\u91cd\u8981\u4f5c\u7528\u3002\u53e6\u5916\uff0c\u4e0eTP53\u91ce\u751f\u578b\u60a3\u8005\u76f8\u6bd4\uff0c\u6211\u4eec\u5728\u643a\u5e26TP53\u7a81\u53d8\u7684\u60a3\u8005\u4e2d\u89c2\u5bdf\u5230\u8f83\u597d\u7684\u7597\u6548\uff0c\u8fd9\u7c7b\u60a3\u8005\u9aa8\u9ad3\u4e2d\u7684\u80bf\u7624\u7ec6\u80de\u8868\u8fbe\u66f4\u9ad8\u7684\u9499\u7f51\u86cb\u767d\u6c34\u5e73\uff0c\u5e76\u4e14\u5177\u6709\u66f4\u9ad8\u6bd4\u4f8b\u7684\u514d\u75ab\u7ec6\u80de\u6d78\u6da6\u3002\u6b64\u9879\u7814\u7a76\u7ed3\u679c\u63ed\u793a\u4e86\u6765\u4f50\u5229\u5355\u6297\u548c\u963f\u624e\u80de\u82f7\u8054\u5408\u6cbb\u7597HR-MDS\u9002\u5e94\u75c7\uff0c\u5728\u8c03\u8282\u80bf\u7624\u7ec6\u80de\u53ca\u514d\u75ab\u7ec6\u80de\u5c42\u9762\u7684\u4f5c\u7528\u673a\u5236\u3002 \u6807\u9898:  Exploration of the… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-83197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/83197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=83197"}],"version-history":[{"count":2,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/83197\/revisions"}],"predecessor-version":[{"id":83201,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/83197\/revisions\/83201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=83197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=83197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=83197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}